Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/1000 Milligrams

Dapagliflozin and Metformin Extended-Release Tablets 10/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HLB Pharm Co., Ltd.
Appearance
Yellow, bilaterally convex, oval-shaped extended-release film-coated tablets
Packaging
30 tablets/box[(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300150 · Approved 2023.01.06 · Insurance code 647304520

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
HLB Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It is especially prescribed as an adjunct therapy for patients who are also following a dietary and exercise regimen. Caution is necessary for adult type 2 diabetes patients who are not achieving adequate blood sugar control and who have or are at risk for cardiovascular disease, and further information on this is available in professional clinical trial data. This medication effectively improves blood sugar control.

How to take

Adult dose

The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication is used for the treatment of diabetes, and while very rare, it can cause a severe condition known as lactic acidosis. Lactic acidosis is characterized by an excessive buildup of lactic acid in the body, and if symptoms occur, immediate medical attention is required. Additionally, there is a risk of hypoglycemia when used in combination with insulin or sulfonylureas, so caution is advised. Symptoms of hypoglycemia include dizziness, tremors, and cold sweats. Patients with impaired kidney function, especially those with moderate to severe impairment, should not use this medication. Regular kidney function tests should be conducted as kidney function can deteriorate rapidly. In cases of acute conditions such as dehydration, severe infection, acute myocardial infarction, or shock, this medication should not be administered, and administration should be suspended for a certain period before and after surgery. Women who are pregnant or breastfeeding should not use this medication, and patients with specific genetic diseases such as lactose intolerance should avoid administration. This medication can cause a decrease in fluid volume and low blood pressure, so elderly patients and those taking diuretics should be especially cautious. Blood pressure and fluid status should be frequently monitored. During the course of treatment with this medication, symptoms of genital and urinary tract infections may occur, requiring immediate treatment if symptoms arise. There is also a possibility of vitamin B12 deficiency; therefore, monitoring serum vitamin B12 levels is recommended during long-term treatment. Excessive alcohol consumption should be avoided as it can increase the risk of lactic acidosis. This medication may affect certain tests (e.g., blood glucose tests), so it is important to inform healthcare professionals about its use during testing. Finally, the safety of this medication in children has not been established, and dosage adjustments may be necessary due to the risk of renal function decline in the elderly. It is crucial to consult with healthcare professionals if any unusual symptoms occur during treatment and to strictly adhere to the prescribed dosage and regimen.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 81 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • reduced vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • pericapsulitis
  • tendinosis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is advisable to keep it at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Yellow, bilaterally convex, oval-shaped extended-release film-coated tablets

Package unit

30 tablets/box[(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.